Regional Oncology Research Center (Social Determinants of Health Supplement)

摘要 约翰霍普金斯大学的西德尼·基梅尔综合癌症中心(SKCCC)致力于癌症 研究、教育和培训以及患者护理，总体目标是创造和应用新的 改善马里兰州癌症预防、筛查、检测、诊断和治疗的知识(The SKCCC集水区)以及全国和世界各地。此应用程序寻求持续癌症 中心支持赠款(CCSG)为SKCCC研究计划和共享资源(SR)提供资金。自.以来 在2016年的上一次CCSG续签时，SKCCC取消了三个研究计划，并创建了一个 新程序。现在，来自约翰·霍普金斯大学34个学术部门的285名成员， 推广七项研究计划：新的癌症侵袭和转移计划，以及已建立的 癌症遗传学和表观遗传学、癌症免疫学、癌症分子和功能学科 影像、肿瘤化学和结构生物学、血液恶性肿瘤和骨髓 移植和癌症预防与控制。十二个SR提供最先进或更好的支持 SKCCC研究和研究人员。SKCCC科学包括对分子的发现研究 人类肿瘤发生的遗传学和表观遗传学、新免疫疗法和其他癌症的临床试验 治疗，以及生活方式对癌症死亡率影响的流行病学分析。在过去的资金 在此期间，SKCCC成员非常高效，撰写了3,775份出版物(23%的内部- 计划性的，22%是计划间的，66%是外部合作者的)。SKCCC研究人员 获得了7850万美元的当前同行审查赠款支持，其中包括来自国家癌症中心的4490万美元 研究所。SKCCC继续将其科学成果送到床边。从平均6,374例新发癌症 从2016-2020年每年接受治疗的患者，平均每年登记1,647名新受试者 介入性研究(26%的新登记癌症患者)；治疗性研究积累了约17%的 癌症患者。此外，SKCCC还成功地促进了少数群体和 在临床研究中服务不足的癌症患者，少数族裔参与的比例略有增加 介入试验(2015年为22.3%，2020年为25.4%)，而非洲裔美国人则增加了介入试验 保持稳定(2015年为15.0%，2020年为15.6%)。展望未来，SKCCC计划：(1)推动新的 基础癌症研究的突破创造了对人类本质的范式转换洞察力 癌症，(2)将这条发现管道转化为改变实践的进步，(3)克服障碍 通过加强创新癌症服务的提供，对癌症结果的差异负责 在整个马里兰州集水区，以及(4)将研究、培训和职业生涯相结合 将生物医学科学家和卫生保健专业人员发展到所有癌症研究领域。

ABSTRACT The Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins is dedicated to cancer research, education and training, and patient care, with the overarching goal of creating and applying new knowledge to improve prevention, screening, detection, diagnosis and treatment of cancer in Maryland (the SKCCC catchment area) and throughout the nation and the world. This application seeks continued Cancer Center Support Grant (CCSG) funding for SKCCC Research Programs and Shared Resources (SRs). Since the previous CCSG renewal in 2016, the SKCCC has eliminated three Research Programs and created one new Program. Now, the 285 Members, from 34 academic departments throughout Johns Hopkins University, populate seven Research Programs: the new Cancer Invasion and Metastasis Program, and the established Programs in Cancer Genetics and Epigenetics, Cancer Immunology, Cancer Molecular and Functional Imaging, Cancer Chemical and Structural Biology, Hematologic Malignancies and Bone Marrow Transplantation, and Cancer Prevention and Control. Twelve SRs provide state-of-the-art-or-better support for SKCCC research and researchers. SKCCC science encompasses discovery research into the molecular genetics and epigenetics of human tumorigenesis, clinical trials of new immunotherapies and other cancer treatments, and epidemiologic analyses of lifestyle influences on cancer mortality. Over the past funding period, SKCCC Members were exceptionally productive, authoring 3,775 publications (23% Intra- Programmatic, 22% Inter-Programmatic and 66% featuring external collaborators). SKCCC researchers garnered $78.5 million in current peer-reviewed grant support, including $44.9 million from the National Cancer Institute. The SKCCC continued to deliver its science to the bedside. From an average 6,374 new cancer patients treated per year from 2016–2020, an average of 1,647 new subjects were enrolled annually to interventional studies (26% of newly registered cancer patients); therapeutic studies accrued some 17% of cancer patients. In addition, the SKCCC has worked successfully to promote inclusion of minority and underserved patients with cancer in clinical research, yielding a slight increase in minority participation in interventional trials (22.3% in 2015 to 25.4% in 2020), while African American accrual to interventional trials remained steady (15.0% in 2015 and 15.6% in 2020). Moving forward, the SKCCC plans: (1) to promote new breakthroughs in fundamental cancer research that create paradigm-shifting insights into the nature of human cancers, (2) to translate this pipeline of discovery into practice-changing advances, (3) to overcome barriers responsible for disparities in cancer outcomes by enhancing the delivery of innovative cancer services throughout the state of Maryland catchment area, and (4) to integrate research training and career development of biomedical scientists and health care professionals into all cancer research endeavors.